At the time of writing, Cyclo Therapeutics Inc [CYTH] stock is trading at $1.19, up 54.55%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CYTH shares have gain 54.55% over the last week, with a monthly amount glided 83.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
For the past year, the stock price of Cyclo Therapeutics Inc fluctuated between $0.55 and $1.92. Currently, Wall Street analysts expect the stock to reach $0.95 within the next 12 months. Cyclo Therapeutics Inc [NASDAQ: CYTH] shares were valued at $1.19 at the most recent close of the market. An investor can expect a potential drop of -20.17% based on the average CYTH price forecast.
Analyzing the CYTH fundamentals
According to Cyclo Therapeutics Inc [NASDAQ:CYTH], the company’s sales were 0.87M for trailing twelve months, which represents an -52.82% plunge. Gross Profit Margin for this corporation currently stands at -2.06% with Operating Profit Margin at -28.34%, Pretax Profit Margin comes in at -28.48%, and Net Profit Margin reading is -28.48%. To continue investigating profitability, this company’s Return on Assets is posted at -4.72, Equity is 7.5 and Total Capital is 1.83. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9567 points at the first support level, and at 0.7233 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4367, and for the 2nd resistance point, it is at 1.6833.
Ratios To Look Out For
It is important to note that Cyclo Therapeutics Inc [NASDAQ:CYTH] has a current ratio of 0.17. In addition, the Quick Ratio stands at 0.16 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 39.14.
